Search

Your search keyword '"Herbelin L"' showing total 17 results

Search Constraints

Start Over You searched for: Author "Herbelin L" Remove constraint Author: "Herbelin L" Search Limiters Full Text Remove constraint Search Limiters: Full Text
17 results on '"Herbelin L"'

Search Results

1. ‘Minimal symptom expression’ in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab

2. Consistent improvement with eculizumab across muscle groups in myasthenia gravis

3. Eculizumab in refractory generalized myasthenia gravis previously treated with rituximab:subgroup analysis of REGAIN and its extension study

4. Eculizumab Improves Fatigue in Refractory Generalized Myasthenia Gravis

5. ‘Minimal symptom expression’ in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab

6. Correction to: Eculizumab improves fatigue in refractory generalized myasthenia gravis (Quality of Life Research, (2019), 28, 8, (2247-2254), 10.1007/s11136-019-02148-2)

7. Randomized Trial of Thymectomy in Myasthenia Gravis

9. Long-term safety and efficacy of eculizumab in generalized myasthenia gravis

10. Resistance exercise in early-stage ALS patients, ALSFRS-R, Sickness Impact Profile ALS-19, and muscle transcriptome: a pilot study.

11. Conducting a bayesian multi-armed trial with response adaptive randomization for comparative effectiveness of medications for CSPN.

12. A Randomized, Double-Blinded, Placebo-Controlled, Cross Over Study Evaluating the Efficacy and Safety of Timolol Ophthalmic Solution as an Acute Treatment of Migraine.

13. Methotrexate Polyglutamation in a Myasthenia Gravis Clinical Trial.

14. A Bayesian comparative effectiveness trial in action: developing a platform for multisite study adaptive randomization.

15. Safety of aerobic exercise in people with diabetic peripheral neuropathy: single-group clinical trial.

16. Non-dystrophic myotonia: prospective study of objective and patient reported outcomes.

17. Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), physician global damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI).

Catalog

Books, media, physical & digital resources